The Pharma Data

MARCH 7, 2022

The IGA results in the equivalent genotype (genetic make-up) and short-hair coat trait seen in some conventionally bred cattle, known as a “slick” coat. director of the FDA’s Center for Veterinary Medicine. “It This is the FDA’s first low-risk determination for enforcement discretion for an IGA in an animal for food use.

Genome 52

Genome Genomics Production Marketing 52

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days.

Genotype 52

Genotype Reagent Genetics Research 52

The Pharma Data

OCTOBER 9, 2021

Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of maribavir (TAK-620) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.

Drugs 52

Drugs Genotype Bioavailability Medicine 52

XTalks

SEPTEMBER 28, 2020

The test was developed by Resolution Bioscience and the company will run test analyses in its labs. The Resolution ctDx Lung assay was developed to offer patients and clinicians with pertinent information that can inform treatment decisions. Related: Liquid Biopsies Help Match Cancer Patients to Phase I Trials.

Gene 105

Gene DNA Life Science Genotype 105

XTalks

MARCH 3, 2021

The US Food and Drug Administration (FDA) has granted approval to Nulibry (fosdenopterin) for reducing the risk of death associated with molybdenum cofactor deficiency type A (MoCD Type A), making it the first treatment for the ultra-rare, genetic metabolic disorder. The approval was granted to BridgeBio Pharma, Inc.

FDA Approval 64

FDA Approval Genotype Clinical Trials Clinical Trials 64

The Pharma Data

MARCH 16, 2022

It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. To support customers performing human genotyping, TIB Molbiol provides custom-made LightSNiP assays for SNP analysis. 2, as well as other mutations, present in the novel B.1.1.529

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

XTalks

APRIL 24, 2023

Approximately 72 percent of rare diseases are genetic, and around 70 percent of rare genetic diseases emerge in childhood. The European Medicines Agency (EMA) initially recommended six novel advanced therapy medicinal products (ATMPs) with orphan designation in 2022, but the orphan designation of one of these ATMPs was later withdrawn.

Gene Therapy 95

Gene Therapy Gene Trials Clinical Trials 95

The Pharma Data

NOVEMBER 18, 2020

HIV drug resistance is caused by changes in the genetic structure of HIV that affects the ability of drugs to block the replication of the virus. An increased use of HIV medicines has been accompanied by the emergence of HIV drug resistance, which has also steadily increased in recent years. . As of December 2019, 25.4 infants. .

Drugs 52

Drugs Genotype Medicine Development 52

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. Li is a prominent neuroscientist and former professor at Johns Hopkins Medicine. Vigil Neuroscience. Led by industry veteran Ivana Magov?evi?-Liebisch

Marketing 52

Marketing In-Vivo Protein In-Vitro 52

XTalks

NOVEMBER 10, 2020

Expeditious and accurate diagnoses are necessary for patients to access healthcare services and treatment options for rare genetic diseases. Increasing the efficiency of case analysis and interpretation is essential to providing timely care for patients with genetic diseases.

Genome 98

Genome Genomics Medicine Genetic Disease 98

The Pharma Data

DECEMBER 9, 2020

The new company, created by Hillhouse Capital Venture Partners, launched this week with a mission to pursue the most promising advances in medicine for underserved patients in Asia and around the world. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

Drug Discovery World

OCTOBER 30, 2023

RA: You’ve recently announced a collaboration with the University of Oxford to access genotype data on women with endometriosis. We previously conducted a hypothesis-free study using genotype data from the UK Biobank, which resulted in the first mechanism-based stratification of endometriosis patients.

Genome 72

Genome Genomics Genotype Clinical Trials 72

XTalks

FEBRUARY 4, 2021

The power of leveraging clinical data to decipher disease mechanisms and fuel drug discovery has rapidly grown in the era of genomics and personalized medicine. Biobanking will continue to play an integral role in accelerating drug discovery and development, which will necessitate access to a larger array of biological samples.

Research 98

Research Biobanking Drugs Genome 98

Drug Discovery World

DECEMBER 12, 2023

Selecting a development candidate for our AATD program is an important milestone for Korro, but more importantly, for patients. KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT.

RNA 52

RNA In-Vivo Genotype Genetics 52

Roots Analysis

AUGUST 31, 2023

Recent advances in DNA sequencing technologies have led to significant developments in healthcare-focused research on precision medicine and diagnostics. Genetic testing can assist individuals in identifying which exercise regime, short and intense or long and consistent, is likely to work the best for them.

Genome 40

Genome Genomics Genetics Gene 40

XTalks

DECEMBER 12, 2023

Moreover, combining biofluid analytes with molecular pathology (genetic biomarkers) allows for the classification and differentiation of neurodegenerative diseases. This is crucial not only for understanding these conditions but also for developing targeted therapeutic strategies.

Trials 111

Trials Clinical Trials Clinical Trials Genetics 111

The Pharma Data

NOVEMBER 24, 2020

PH1 is an ultra-rare genetic disease characterized by oxalate overproduction. Oxlumo marks our third FDA approval in less than three years, positioning us to meet or exceed our Alnylam 2020 strategy and goals, and further highlighting the productivity of our RNAi platform and the speed at which we can bring innovative medicines to patients.

FDA Approval 52

FDA Approval Production RNA Medicine 52

Drug Discovery World

JULY 15, 2022

The Telomere-to-Telomere (T2T) Consortium successfully sequenced about 200 million remaining base pairs to approach 100% of the human genome by using the newly developed long read sequencing (LRS) technology 3,4,5. Telomeres play an important role in normal genome function and development of human disease.

Genome 52

Genome Genomics DNA Containment 52